Literature DB >> 8410272

Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.

D Casara1, D Rubello, G Saladini, G Masarotto, A Favero, M E Girelli, B Busnardo.   

Abstract

We studied 134 patients with differentiated thyroid cancer and pulmonary metastases. All were treated with total or near total thyroidectomy, radioiodine and L-thyroxine. The prognostic value of the following variables in three groups of patients were evaluated by univariate and multivariate analysis: age at diagnosis, sex, histologic type, tumor extension, cervical lymph node metastases, mediastinic metastases, presence of metastases in distant sites other than lungs (multiple distant metastases) and morphological (chest x-rays) and functional (131I uptake) features of lung metastases. Univariate analysis identified patient age (p < 0.0001), morphological and functional features of lung metastases (p < 0.0001), presence of multiple distant metastases (p < 0.0001) and histologic type (p = 0.04) as significant prognostic factors. Multivariate analysis showed only morphological (p = 0.0014) and functional (p < 0.0001) features of lung metastases and the presence of multiple distant metastases (p = 0.01) as significant and independent variables. The data show that early (pre-radiological) scintigraphic diagnosis and 131I therapy of lung metastases appear to be the most important elements in obtaining both a significant improvement in survival rate and a prolonged disease-free time interval in these patients.

Entities:  

Mesh:

Year:  1993        PMID: 8410272

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  47 in total

1.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?

Authors:  C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07       Impact factor: 9.236

2.  Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.

Authors:  Marcel P M Stokkel; Robbert B Verkooijen; Jan W A Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-26       Impact factor: 9.236

3.  Radioiodine Scan Index: A Simplified, Quantitative Treatment Response Parameter for Metastatic Thyroid Carcinoma.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-04-28

4.  A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.

Authors:  Paolo Zanotti-Fregonara; Gaia Grassetto; Elif Hindié; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02       Impact factor: 9.236

Review 5.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 6.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 8.  Thyroid cancer: a review of treatment and follow-up.

Authors:  L Vini; C Harmer; V R McCready
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

9.  Differentiated thyroid cancer presenting with distant metastases: a population analysis over two decades.

Authors:  Paolo Goffredo; Julie A Sosa; Sanziana A Roman
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

10.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.